Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BAY 3563254

Drug Profile

BAY 3563254

Alternative Names: 225Ac-PSMA-Trillium; Ac 225 conjugated small molecule - Bayer; Actinium-labeled PSMA-targeted alpha therapy - Bayer; BAY-3563254; PSMA SMOL TAC - Bayer

Latest Information Update: 11 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nora Therapeutics; SMA Therapeutics
  • Developer Bayer
  • Class Antineoplastics; Radioisotopes; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Prostate cancer

Most Recent Events

  • 07 Mar 2024 Phase-I clinical trials in Prostate cancer (Late-stage disease, Hormone refractory, Second-line therapy or greater, Metastatic disease) in Canada (IV) (NCT06217822) (EudraCT2023-507486-26-00)
  • 23 Jan 2024 Bayer plans a phase I PAnTHA trial for Prostate cancer (Second-line therapy or greater, Late-stage disease, Metastatic disease) in Belgium, Canada and United Kingdom (NCT06217822)
  • 28 Nov 2023 Phase-0 for Prostate cancer (Late-stage disease) (Parenteral) prior to November 2023(Parenteral) (Bayer pipeline, November 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top